Fragile X syndrome: The GABAergic system and circuit dysfunction

Developmental Neuroscience

Volumn 33, Issue 5, 2011, Pages 349-364

  Paluszkiewicz, Scott M ^a,b   Martin, Brandon S ^a,b   Huntsman, Molly M ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amygdala; Autism spectrum disorders; Cerebral cortex; Developmental disorder; Fragile X mental retardation protein; Inhibition; Synapse

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; ARBACLOFEN; BENZODIAZEPINE DERIVATIVE; GABOXADOL; GANAXOLONE; MESSENGER RNA; METABOTROPIC RECEPTOR 5; NIPECOTIC ACID; RILUZOLE; TAURINE; TIAGABINE; VIGABATRIN;

4 AMINOBUTYRIC ACID RELEASE; AMYGDALOID NUCLEUS; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; AUTISM; BEHAVIOR; BRAIN CORTEX; CATAMENIAL EPILEPSY; COMPLEX PARTIAL SEIZURE; CORPUS STRIATUM; DRUG TARGETING; ELECTROPHYSIOLOGY; FOREBRAIN; FRAGILE X SYNDROME; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GENE EXPRESSION; GLIA CELL; HIPPOCAMPUS; HUMAN; INFANTILE SPASM; INSOMNIA; INTERNEURON; KNOCKOUT MOUSE; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NONHUMAN; PHENOTYPE; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REBOUND; REVIEW; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMATOSENSORY CORTEX; SUBICULUM; SYNAPSE;

AMYGDALA; ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; HUMANS; NEURONAL PLASTICITY; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 83055163327     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000329420     Document Type: Review

References (186)

1. Abitbol M, Menini C, Delezoide AL, Rhymer T, Vekemans M, Mallet J (1993): Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain. Nat Genet 4: 147-153.
2. Adusei DC, Pacey LK, Chen D, Hampson DR (2010): Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 59: 167-171.
3. Agulhon C, Blanchet P, Kobetz A, Marchant D, Faucon N, Sarda P, Moraine C, Sittler A, Bianclana V, Malafosse A, Abitbol M (1999): Expression of FMR1, FXR1, and FXR2 genes in human prenatal tissues. J Neuropathol Exp Neurol 58: 867-880.
4. Akerman CJ, Cline HT (2006): Depolarizing GABAergic conductances regulate the balance of excitation to inhibition in the developing retinotectal circuit in vivo. J Neurosci 26: 5117-5130.
5. Akerman CJ, Cline HT (2007): Refining the roles of GABAergic signaling during neural circuit formation. Trends Neurosci 30: 382-389.
6. Bacci A, Huguenard JR, Prince DA (2005): Modulation of neocortical interneurons: extrinsic influences and exercises in self-control. Trends Neurosci 28: 602-610.
7. Bagni C, Greenough WT (2005): From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci 6: 376-387.
8. Bakker CE, de Diego Otero Y, Bontekoe C, Raghoe P, Luteijn T, Hoogeveen AT, Oostra BA, Willemsen R (2000): Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse. Exp Cell Res 258: 162-170.
9. Bassell GJ, Warren ST (2008): Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60: 201-214.
10. Batista-Brito R, Fishell G (2009): The developmental integration of cortical interneurons into a functional network. Curr Top Dev Biol 87: 81-118.
11. Behar TN, Schaffner AE, Scott CA, Greene CL, Barker JL (2000): GABA receptor antagonists modulate postmitotic cell migration in slice cultures of embryonic rat cortex. Cereb Cortex 10: 899-909.
12. Behar TN, Schaffner AE, Scott CA, O'Connell C, Barker JL (1998): Differential response of cortical plate and ventricular zone cells to GABA as a migration stimulus. J Neurosci 18: 6378-6387.
13. Behar TN, Smith SV, Kennedy RT, McKenzie JM, Maric I, Barker JL (2001): GABA(B) receptors mediate motility signals for migrating embryonic cortical cells. Cereb Cortex 11: 744-753.
14. Beierlein M, Gibson JR, Connors BW (2003): Two dynamically distinct inhibitory networks in layer 4 of the neocortex. J Neurophysiol 90: 2987-3000.
15. Belelli D, Lambert JJ (2005): Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 6: 565-575.
16. Belmonte MK, Bourgeron T (2006): Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci 9: 1221-1226.
17. Ben-Ari Y (2002): Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci 3: 726-739.
18. Berry-Kravis E (2002): Epilepsy in fragile X syndrome. Dev Med Child Neurol 44: 724-728.
19. Berry-Kravis E, Raspa M, Loggin-Hester L, Bishop E, Holiday D, Bailey DB (2010): Seizures in fragile X syndrome: characteristics and comorbid diagnoses. Am J Intellect Dev Disabil 115: 461-472.
20. Bettler B, Kaupmann K, Mosbacher J, Gassmann M (2004): Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev 84: 835-867.
21. Biagini G, Panuccio G, Avoli M (2010): Neurosteroids and epilepsy. Curr Opin Neurol 23: 170-176.
22. Blundell J, Tabuchi K, Bolliger MF, Blaiss CA, Brose N, Liu X, Südhof TC, Powell CM (2009): Increased anxiety-like behavior in mice lacking the inhibitory synapse cell adhesion molecule neuroligin 2. Genes Brain Behav 8: 114-126.
23. Bosman LW, Heinen K, Spijker S, Brussaard AB (2005): Mice lacking the major adult GABAA receptor subtype have normal number of synapses, but retain juvenile IPSC kinetics until adulthood. J Neurophysiol 94: 338-346.
24. Bosman LW, Rosahl TW, Brussaard AB (2002): Neonatal development of the rat visual cortex: synaptic function of GABAA receptor alpha subunits. J Physiol (Lond) 545: 169-181.
25. Brown N, Kerby J, Bonnert TP, Whiting PJ, Wafford KA (2002): Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. Br J Pharmacol 136: 965-974.
26. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST (2001): Microarray identification of FMRPassociated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107: 477-487.
27. Buckmaster PS, Jongen-Rêlo AL (1999): Highly specific neuron loss preserves lateral inhibitory circuits in the dentate gyrus of kainateinduced epileptic rats. J Neurosci 19: 9519-9529.
28. Budimirovic DB, Bukelis I, Cox C, Gray RM, Tierney E, Kaufmann WE (2006): Autism spectrum disorder in Fragile X syndrome: differential contribution of adaptive socialization and social withdrawal. Am J Med Genet A 140A:1814-1826.
29. Bureau I, Shepherd GM, Svoboda K (2008): Circuit and plasticity defects in the developing somatosensory cortex of FMR1 knock-out mice. J Neurosci 28: 5178-5188.
30. Cardin JA, Carlén M, Meletis K, Knoblich UZ, Deisseroth K, Tsai LH, Moore CI (2009): Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 459: 663-667.
31. Centonze D, Rossi S, Mercaldo V, Napoli I, Ciotti MT, De Chiara V, Musella A, Prosperetti C, Calabresi P, Bernardi G, Bagni C (2008): Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry 63: 963-973.
32. Chang S, Bray SM, Li Z, Zarnescu DC, He C, Jin PW (2008): Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 4: 256-263.
33. Chao HT, Chen H, Samaco RC, Xue M, Chahrour M, Yoo J, Neul JL, Gong S, Lu HC, Heintz N, Ekker M, Rubenstein JL, Noebels JL, Rosenmund C, Zoghbi HY (2010): Dysfunction in GABA signalling mediates autism- like stereotypies and Rett syndrome phenotypes. Nature 468: 263-269.
34. Chattopadhyaya B, Di Cristo G, Higashiyama H, Knott GWK, Welker E, Huang ZJ (2004): Experience and activity-dependent maturation of perisomatic GABAergic innervation in primary visual cortex during a postnatal critical period. J Neurosci 24: 9598-9611.
35. Chattopadhyaya B, Di Cristo G, Wu CZ, Knott GWK, Fu Y, Palmiter RDH (2007): GAD67- mediated GABA synthesis and signaling regulate inhibitory synaptic innervation in the visual cortex. Neuron 54: 889-903.
36. Chih B, Engelman H, Scheiffele P (2005): Control of excitatory and inhibitory synapse formation by neuroligins. Science 307: 1324-1328.
37. Chiron C, Dumas C, Jambaqué I, Mumford J, Dulac O (1997): Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 26: 389-395.
38. Christie SB, Akins MR, Schwob JE, Fallon JR (2009): The FXG: a presynaptic fragile X granule expressed in a subset of developing brain circuits. J Neurosci 29: 1514-1524.
39. Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK (2005): Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci 25: 8048-8055.
40. Chubykin AA, Atasoy D, Etherton MR, Brose N, Kavalali ET, Gibson JR, Südhof TC (2007): Activity-dependent validation of excitatory versus inhibitory synapses by neuroligin-1 versus neuroligin-2. Neuron 54: 919-931.
41. Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ, Greenough WT (1997): Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci USA 94: 5401-5404.
42. Cossart R, Dinocourt C, Hirsch JC, Merchan- Perez A, De Felipe JB-A, Esclapez M, Bernard C (2001): Dendritic but not somatic GABAergic inhibition is decreased in experimental epilepsy. Nat Neurosci 4: 52-62.
43. Curia G, Papouin T, Sequela P, Avoli M (2008): Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex 19: 1515-1520.
44. Dahlhaus R, El-Husseini A (2010): Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome. Behav Brain Res 208: 96-105.
45. Dani VS, Chang Q, Maffei A, Turrigiano GG, Jaenisch R, Nelson SB (2005): Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci USA 102: 12560-12565.
46. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell SB (2001): Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 107: 555-557.
47. Deacon S, Staner L, Staner C, Legters A, Loft H, Lundahl J (2007): Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia. Sleep 30: 281-287.
48. De Felipe J, Marco P, Fairén A, Jones EG (1997): Inhibitory synaptogenesis in mouse somatosensory cortex. Cereb Cortex 7: 619-634.
49. De Rubeis S, Bagni C (2010): Fragile X mental retardation protein control of neuronal mRNA metabolism: insights into mRNA stability. Mol Cell Neurosci 43: 43-50.
50. Desai NS, Casimiro TM, Gruber SM, Vanderklish PW (2006): Early postnatal plasticity in neocortex of Fmr1 knockout mice. J Neurophysiol 96: 1734-1745.
51. de Vries BB, Halley DJ, Oostra B, Niermeijer MF (1998): The fragile X syndrome. J Med Genet 35: 579-589.
52. Devys D, Lutz Y, Rouyer N, Bellocq JP, Mandel JL (1993): The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet 4: 335-340.
53. D'Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA, Kooy RF (2006): Decreased expression of the GABAa receptor in fragile X syndrome. Brain Res 1121: 238-245.
54. D'Hulst C, Heulens I, Brouwer JR, Willemsen R, De Geest N, Reeve SP, De Deyn PP, Hassan BA, Kooy RF (2009): Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res 1253: 176-183.
55. Dolen G, Bear MF (2008): Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol (Lond) 586: 1502-1508.
56. Dunning DD, Hoover CL, Soltesz I, Smith MAOD, (1999): GABA(A) receptor-mediated miniature postsynaptic currents and alpha- subunit expression in developing cortical neurons. J Neurophysiol 82: 3286-3297.
57. Ehrlich I, Humeau Y, Grenier FC, Herry C, Luthi A (2009): Amygdala inhibitory circuits and the control of fear memory. Neuron 62: 757-771.
58. El Idrissi A, Boukarrou L, Dokin C, Brown WT (2009): Taurine improves congestive functions in a mouse model of fragile X syndrome. Adv Exp Med Biol 643: 191-198.
59. El Idrissi A, Ding XH, Scalia J, Trenkner E, Brown WT, Dobkin C (2005): Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci Lett 377: 141-146.
60. El Idrissi A, L'Amoreaux WJ (2008): Selective resistance of taurine-fed mice to isoniazidepotentiated seizures: in vivo functional test for the activity of glutamic acid decarboxylase. Neuroscience 156: 693-699.
61. El Idrissi A, Yan X, Sidime F, L'Amoreaux W (2010): Neuro-endocrine basis for altered plasma glucose homeostasis in the Fragile X mouse. J Biomed Sci 17(suppl 1):S8.
62. Erickson CA, Weng N, Weiler IJ, Greenough WT, Stigler KA, Wink LKM (2010): Openlabel riluzole in fragile X syndrome. Brain Res 2011; 1380: 264-270.
63. Farrant M, Nusser Z (2005): Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 6: 215-229.
64. Feng Y, Gutekunst CA, Eberhart DE, Yi H, Warren ST, Hersch SM (1997): Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci 17: 1539-1547
65. French JA, Mosier M, Walker S, Sommerville K, Sussman N (1996): A double-blind, placebocontrolled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. Neurology 46: 54-61.
66. Frisén L, Malmgren K (2003): Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81: 466-473.
67. Fritschy JM, Brunig I (2003): Formation and plasticity of GABAergic synapses: physiological mechanisms and pathophysiological implications. Pharmacol Ther 98: 299-323.
68. Fritschy JM, Johnson DK, Mohler H, Rudolph U (1998): Independent assembly and subcellular targeting of GABA(A)-receptor subtypes demonstrated in mouse hippocampal and olfactory neurons in vivo. Neurosci Lett 249: 99-102.
69. Fritschy JM, Paysan J, Enna A, Mohler H (1994): Switch in the expression of rat GABAA-receptor subtypes during postnatal development: an immunohistochemical study. J Neurosci 14: 5302-5324.
70. Galarreta M, Hestrin S (1999): A network of fastspiking cells in neocortex connected by electrical synapses. Nature 402: 72-75.
71. Galvez R, Gopal AR, Greenough WT (2003): Somatosensory cortical barrel dendritic abnormalities in a mouse model of the fragile X mental retardation syndrome. Brain Res 971: 83-89.
72. Gantois I, Vandesompele J, Speleman F, Reyniers E, D'Hooge R, Severijnen LA, Willemsen R, Tassone F, Kooy RF (2006): Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis 21: 346-357.
73. Gibson JR, Bartley AF, Hays SA, Huber KM (2008): Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J Neurophysiol 100: 2615-2626.
74. Gibson JR, Beierlein M, Connors BW (1999): Two networks of electrically coupled inhibitory neurons in neocortex. Nature 402: 75-79.
75. Gibson JR, Huber KM, Südhof T (2009): Neuroligin- 2 deletion selectively decreases inhibitory synaptic transmission originating from fast-spiking but not from somatostatin-positive interneurons. J Neurosci 29: 13883-13897.
76. Glykys J, Mody I (2006): Hippocampal network hyperactivity after selective reduction of tonic inhibition in GABA A receptor alpha5 subunit-deficient mice. J Neurophysiol 95: 2796-2807.
77. Glykys J, Mody I (2007): Activation of GABAA receptors: views from outside the synaptic cleft. Neuron 56: 763-770.
78. Gogolla N, Leblanc JJ, Quast KB, Südhof T, Fagiolini M, Hensch TK (2009): Common circuit defect of excitatory-inhibitory balance in mouse models of autism. J Neurodev Disord 1: 172-181.
79. Golshani P, Truong H, Jones EG (1997): Developmental expression of GABA(A) receptor subunit and GAD genes in mouse somatosensory barrel cortex. J Comp Neurol 383: 199-219.
80. Gothelf D, Furfaro JA, Hoeft F, Eckert MA, Hall SS, O'Hara R, Erba HW, Ringel J, Hayashi KM, Patnaik S, Golianu B, Kraemer HC, Thompson PM, Piven J, Reiss AL (2008): Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP). Ann Neurol 63: 40-51.
81. Gruss M, Braun K (2004): Age- and region-specific imbalances of basal amino acids and monoamine metabolism in limbic regions of female Fmr1 knock-out mice. Neurochem Int 45: 81-88.
82. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M (2009): Advances in the treatment of fragile X syndrome. Pediatrics 123: 378-390.
83. Hagerman PJ, Stafstrom CE (2009): Origins of epilepsy in fragile X syndrome. Epilepsy Curr 9: 108-112.
84. Harlow EG, Till SM, Russell TA, Wijetunge LS,Kind P, Contractor A (2010): Critical period plasticity is disrupted in the barrel cortex of Fmr1 knockout mice. Neuron 65: 385-398.
85. Haydar TF, Wang F, Schwartz ML, Rakic P (2000): Differential modulation of proliferation in the neocortical ventricular and subventricular zones. J Neurosci 20: 5764-5774.
86. Heinen K, Bosman LW, Spijker S, van Pelt J, Smit AB, Voorn P, Baker RE, Brussaard AB (2004): GABAA receptor maturation in relation to eye opening in the rat visual cortex. Neuroscience 124: 161-171.
87. Hennou S, Khalilov I, DIabira D, Ben-Ari Y, Goz lan H (2002): Early sequential formation of functional GABA(A) and glutamatergic synapses on CA1 interneurons of the rat foetal hippocampus. Eur J Neurosci 16: 197-208.
88. Hevers W, Lüddens H (1998): The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol Neurobiol 18: 35-86.
89. Hinds HL, Ashley CT, Sutcliffe JS, Nelson DL, Warren ST, Housman DE, Schalling M (1993): Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet 3: 36-43.
90. Hines RM, Wu L, Hines DJ, Steenland H, Mansour S, Dahlhaus R, Singaraja RR, Cao X, Sammler E, Hormuzdi SG, Zhuo M, El-Husseini A (2008): Synaptic imbalance, stereotypies, and impaired social interactions in mice with altered neuroligin 2 expression. J Neurosci 28: 6055-6067.
91. Hoeft F, Hernandez A, Parthsarathy S, Watson CL, Hall SS, Reiss AL (2007): Fronto-striatal dysfunction and potential compensatory mechanisms in male adolescents with fragile X syndrome. Hum Brain Mapp 28: 543-554.
92. Hollrigel GS, Soltesz I (1997): Slow kinetics of miniature IPSCs during early postnatal development in granule cells of the dentate gyrus. J Neurosci 17: 5119-5128.
93. Huang ZJ (2009): Activity-dependent development of inhibitory synapses and innervations pattern: role of GABA signalling and beyond. J Physiol (Lond) 587: 1881-1888.
94. Huber KM, Gallagher SM, Warren ST, Bear MF (2002): Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99: 7746-7750.
95. Huntsman MM, Huguenard JR (2000): Nucleusspecific differences in GABA(A)-receptormediated inhibition are enhanced during thalamic development. J Neurophysiol 83: 350-358.
96. Huntsman MM, Muñoz A, Jones EG (1999): Temporal modulation of GABA A receptor subunit gene expression in developing monkey cerebral cortex. Neuroscience 91: 1223-1245.
97. Irwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, Larsen BP, Kooy RF, Willems PJ, Cras P, Kozlowski PB, Swain RA, Weiler IJ, Greenough WT (2001): Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile- X syndrome: a quantitative examination. Am J Med Genet 98: 161-167.
98. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B (2011): Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011; 3: 64ra1.
99. Jahn K, Schlesinger F, Jin LJ, Dengler R, Bufler J, Krampfl K (2008): Molecular mechanisms of interaction between the neuroprotective substance riluzole and GABA(A)-receptors. Naunyn Schmiedebergs Arch Pharmacol 378: 53-63.
100. Kawaguchi Y, Kubota Y (1997): GABAergic cell subtypes and their synaptic connections in rat frontal cortex. Cereb Cortex 7: 476-486.
101. Kerner JA, Standaert DG, Penney JBJ, Young AB, Labdwehrmeyer GB (1997): Expression of group one metabotropic glutamate receptor subunit mRNAa in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. Mol Brain Res 48: 259-269.
102. Kirischuk S, Jüttner R, Grantyn R (2005): Timematched pre- and postsynaptic changes of GABAergic synaptic transmission in the developing mouse superior colliculus. J Physiol (Lond) 563: 795-807.
103. Klausberger T, Roberts JD, Somogyi P (2002): Cell type- and input-specific differences in the number and subtypes of synaptic GABA(A) receptors in the hippocampus. J Neurosci 22: 2513-252
104. Kobayashi M, Hamada T, Kogo M, Yanagawa Y, Obata K, Kang Y (2008): Developmental profile of GABA A -mediated synaptic transmission in pyramidal cells of the somatosensory cortex. Eur J Pharmacol 28: 849-861.
105. L'Amoreaux WJ, Marsillo A, El Idrissi A (2010): Pharmacological characterization of GABAA receptors in taurine-fed mice. J Biomed Sci 17(suppl 1):S14.
106. Laurie DJ, Wisden W, Seeburg PH (1992): The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J Neurosci 12: 4151-4172.
107. Ledoux J (2003): The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 23: 727-738.
108. Lewis DA, Hashimoto T, Volk DW (2005): Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312-324.
109. Li J, Pelletier MR, Perez Velaquez JL, Carlen PL (2002): Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci 19: 138-151.
110. Li P, Rudolph U, Huntsman MM (2009): Longterm sensory deprivation selectively rearranges functional inhibitory circuits in mouse barrel cortex. Proc Natl Acad Sci USA 106: 12156-12161.
111. Li RW, Yu W, Christie S, Miralles CP, Bai J, Loturco JJ, De Blas AL (2005): Disruption of postsynaptic GABA receptor clusters leads to decreased GABAergic innervation of pyramidal neurons. J Neurochem 95: 756-770.
112. Liao L, Park SK, Xu T, Vanderklish P, Yates JRI (2008): Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc Natl Acad Sci USA 105: 15281-15286.
113. López-Bendito G, Luján R, Shigemoto R, Ganter P, Paulson O, Molnár Z (2003): Blockade of GABA(B) receptors alters the tangential migration of cortical neurons. Cereb Cortex 13: 932-942.
114. LoTurco JJ, Owens DF, Heath MJ, Davis MB, Kriegstein AR (1995): GABA and glutamate depolarize cortical progenitor cells and inhibit DNA synthesis. Neuron 15: 1287-1298.
115. Lundahl J, Staner L, Staner C, Loft H, Deacon S (2007): Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia. Psychopharmacology 195: 139-146.
116. Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, Bernardi G, Bagni C, Centonze D (2010): Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology 35: 1500-1509.
117. Maffei A, Turrigiano GG (2008): Multiple modes of network homeostasis in visual cortical layer 2/3. J Neurosci 28: 4377-4384.
118. Maffei A, Nataraj K, Nelson SB, Turrigiano GG (2006): Potentiation of cortical inhibition by visual deprivation. Nature 443: 81-84.
119. Manent JB, Demarque M, Jorquera I, Pellegrino C, Ben-Ari Y, Aniksztejn L, Represa A (2005): A noncanonical release of GABA and glutamate modulates neuronal migration. J Neurosci 25: 4755-4765.
120. Mantz J, Laudenbach V, Lecharny JB, Henzel D, Desmonts JM (1994): Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. Eur J Pharmacol 257:R7-R8
121. Marín O, Yaron A, Bagri A, Tessier-Lavigne M, Rubenstein JL (2001): Sorting of striatal and cortical interneurons regulated by semaphorin- neuropilin interactions. Science 293: 872-875.
122. Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C (2004): Interneurons of the neocortical inhibitory system. Nat Rev Neurosci 5: 793-807.
123. McNaughton CH, Moon J, Strawderman MS, Maclean KN, Evans J, Strupp BJ (2008): Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. Behav Neurosci 122: 293-300.
124. Medrihan L, Tantalaki E, Aramuni G, Sargysan V, Dudanova IM, Zhang W (2008): Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J Neurophysiol 99: 112-121.
125. Menon V, Leroux J, White CD, Reiss AL (2004): Frontostriatal deficits in fragile X syndrome: relation to FMR1 gene expression. Proc Natl Acad Sci USA 101: 3615-3620.
126. Micheva KD, Beaulieu C (1995): An anatomical substrate for experience-dependent plasticity of the rat barrel field cortex. Proc Natl Acad Sci USA 92: 11834-11838.
127. Micheva KD, Beaulieu C (1996): Quantitative aspects of synaptogenesis in the rat barrel field cortex with special reference to GABA circuitry. J Comp Neurol 373: 340-354.
128. Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, Lagenaur C, Tretter V, Sieghart W, Anagnostaras SG, Sage JR, Fanselow MS, Guidotti A, Spigelman I, Li Z, De- Lorey TM, Olsen RW, Homanics GE (1999): Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci USA 96: 12905-12910.
129. Miller LJ, McIntosh DN, McGrath J, Shyu V, Lampe M, Taylor AK, Tassone F, Neitzel K, Stackhouse T, Hagerman RJ (1999): Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: A preliminary report. Am J Med Genet 83: 268-279.
130. Misgeld U, Bijak M, Jarolimek W (1995): A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Prog Neurobiol 46: 423-462.
131. Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, Carbonetto S, Weiler IJ, Greenough WT, Eberwine J (2003): RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 37: 417-431.
132. Moretti P, Zoghbi HY (2006): MeCP2 dysfunction in Rett syndrome and related disorders. Curr Opin Genet Dev 16: 276-281.
133. Moy SS, Nadler JJ (2008): Advances in behavioral genetics: mouse models of autism. Mol Psychiatry 13: 4-26.
134. Moy SS, Nadler JJ, Young NB, Nonneman RJ, Grossman AW, Murphy DL, D'Ercole AJ, Crawley JN, Magnuson TR, Lauder JM (2009): Social approach in genetically engineered mouse lines relevant to autism. Genes Brain Behav 8: 129-142.
135. Muller JF, Mascagni F, McDonald AJ (2006): Pyramidal cells of the rat basolateral amygdala: synaptology and innervation by parvalbumin- immunoreactive interneurons. J Comp Neurol 494: 635-650.
136. Muller JF, Mascagni F, McDonald AJ (2007): Postsynaptic targets of somatostatin-containing interneurons in the rat basolateral amygdala. J Comp Neurol 500: 513-529.
137. Musumeci SA, Colognola RM, Ferri R, Gigli GL, Petrella MA, Sanfilippo S, Bergonzi P, Tassinari CA (1988): Fragile-X syndrome: a particular epileptogenic EEG pattern. Epilepsia 29: 41-47.
138. Musumeci SA, Hagerman RJ, Ferri R, Bosco P, Dalla Bernardina B, Tassinari CA, De Sarro GB, Elia M (1999): Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 40: 1092-1099.
139. Nemeroff C (2003): The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 37: 133-146.
140. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJ, Sonnewald U, Braestrup C (1991): Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 196: 257-266.
141. Nusser Z, Sieghart W, Benke D, Fritschy JM, Somogyi P (1996): Differential synaptic localization of two major gamma-aminobutyric acid type A receptor alpha subunits on hippocampal pyramidal cells. Proc Natl Acad Sci USA 93: 11939-11944.
142. Nyiri G, Freund TF, Somogyi P (2001): Inputdependent synaptic targeting of alpha(2)- subunit-containing GABA(A) receptors in synapses of hippocampal pyramidal cells of the rat. Eur J Neurosci 13: 428-442.
143. Olmos-Serrano JL, Paluszkiewicz SM, Kaufmann WE, Corbin JG, Huntsman MM (2010): Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile x syndrome. J Neurosci 30: 9929-9938.
144. Ortinski PI, Lu C, Takagaki K, Fu Z, Vicini S (2004): Expression of distinct alpha subunits of GABAA receptor regulates inhibitory synaptic strength. J Neurophysiol 92: 1718-1727.
145. Pacey LK, Heximer SP, Hampson DR (2009): Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 76: 18-24.
146. Padgett CL, Slesinger PA (2010): GABAB receptor coupling to G-proteins and ion channels. Adv Pharmacol 58: 123-147.
147. Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST (1999): Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 94: 185-192.
148. Pascual M, Pozas E, Soriano E (2005): Role of class 3 semaphorins in the development and maturation of the septohippocampal pathway. Hippocampus 15: 184-202.
149. Porter JT, Johnson CK, Agmon A (2001): Diverse types of interneurons generate thalamusevoked feedforward inhibition in the mouse barrel cortex. J Neurosci 21: 2699-2710.
150. Poulopoulos A, Aramuni G, Meyer G, Soykan T, Hoon M, Papadopoulos T, Zhang M, Paarmann I, Fuchs C, Harvey K, Jedlicka P, Schwarzacher SW, Betz H, Harvey RJ, Brose N, Zhang W, Varoqueaux F (2009): Neuroligin 2 drives postsynaptic assembly at perisomatic inhibitory synapses through gephyrin and collybistin. Neuron 63: 628-642.
151. Reddy DS (2010): Neurosteroids: endogenous role in the human brain and therapeutic potentials.Prog Brain Res 186: 113-137.
152. Reiss AL, Abrams MT, Greenlaw R, Freund L, Denckla MB (1995): Neurodevelopmental effects of the FMR-1 full mutation. Nat Med 1: 159-167.
153. Reiss AL, Lee J, Freund L (1994): Neuroanatomy of fragile X syndrome: the temporal lobe. Neurology 44: 1317-1324.
154. Rivera C, Voipio J, Payne JA, Ruusuvuori E, Lahtinen H, Lamsa K, Pirvola U, Saarma M, Kaila K (1999): The K + /Cl - co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 397: 251-255.
155. Rubenstein JLR, Merzenich MM (2003): Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2: 255-267.
156. Rudolph U, Möhler H (2006): GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol 6: 18-23.
157. Schütt J, Falley K, Richter D, Kreienkamp HJ, Kindler S (2009): Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J Biol Chem 284: 25479-25487.
158. Selby L, Zhang C, Sun QQ (2007): Major defects in neocortical GABAergic circuits in mice lacking the fragile X mental retardation protein. Neurosci Lett 412: 227-232.
159. Semyanov A, Walker MC, Kullmann DM, Silver RA (2004): Tonically active GABA A receptors: modulating gain and maintaining the tone. Trends Neurosci 27: 262-269.
160. Sieghart W, Sperk G (2002): Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem 2: 795-816.
161. Sohal VS, Zhang F, Yizhar O, Deisseroth K (2009): Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459: 698-702.
162. Somogyi P, Klausberger T (2005): Defined types of cortical interneurone structure space and spike timing in the hippocampus. J Physiol (Lond) 562: 9-26.
163. Somogyi P, Tamás G, Lujan R, Buhl EH (1998): Salient features of synaptic organisation in the cerebral cortex. Brain Res Rev 26: 113-135.
164. Stinehelfer S, Vruwink M, Burette A (2000): Immunolocalization of mGluR1alpha in specific populations of local circuit neurons in the cerebral cortex. Brain Res 861: 37-44.
165. Südhof T (2008): Neuroligins and neurexins link synaptic function to cognitive disease. Nature 455: 903-911.
166. Sun QQ, Zhang Z, Jiao Y, Zhang C, Szabo G, Erdelyi F (2009): Differential metabotropic glutamate receptor expression and modulation in two neocortical inhibitory networks. J Neurophysiol 101: 2679-2692.
167. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S (2010): Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci USA 107: 11591-11596.
168. Tamamaki N, Fujimori K, Nojyo Y, Kaneko T, Takauji R (2003): Evidence that Sema3A and Sema3F regulate the migration of GABAergic neurons in the developing neocortex. J Comp Neurol 455: 238-248.
169. Tamanini F, Willemsen R, van Unen L, Bontekoe C, Galjaard H, Oostra B, Hoogeveen AT (1997): Differential expression of FMR1, FXR1 and FXR2 proteins in human brain and testis. Hum Mol Genet 6: 1315-1322.
170. Trigo FF, Marty A, Stell BM (2008): Axonal GABAA receptors. Eur J Neurosci 28: 841-848.
171. Tyzio R, Represa A, Jorquera I, Ben-Ari Y, Gozlan H, Aniksztejn L (1999): The establishment of GABAergic and glutamatergic synapses on CA1 pyramidal neurons is sequential and correlates with the development of the apical dendrite. J Neurosci 19: 10372-10382.
172. Varoqueaux F, Jamain S, Brose N (2004): Neuroligin 2 is exclusively localized to inhibitory synapses. Eur J Cell Biol 83: 449-456.
173. Verkerk A, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, Eussen BE, van Ommen GB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galjaard H, Caskey CT, Nelson DL, Oostra BA, Warren ST (1991): Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65: 905-914.
174. Vicini S, Ferguson C, Prybylowski K, Kralic J, Morrow AL, Homanics GE (2001): GABA(A) receptor alpha1 subunit deletion prevents developmental changes of inhibitory synaptic currents in cerebellar neurons. J Neurosci 21: 3009-3016.
175. Wang C, Shimizu-Okabe C, Watanabe K, Okabe A, Matsuzaki H, Ogawa T, Mori N, Fukuda A, Sato K (2002): Developmental changes in KCC1, KCC2, and NKCC1 mRNA expressions in the rat brain. Dev Brain Res 139: 59-66.
176. Wang DD, Kriegstein AR (2008): GABA regulates excitatory synapse formation in the neocortex via NMDA receptor activation. J Neurosci 28: 5547-5558.
177. Wang DD, Kriegstein AR (2009): Defining the role of GABA in cortical development. J Physiol (Lond) 587: 1873-1879.
178. Wang H, Ku L, Osterhout DJ, Li W, Ahmadian A, Liang Z, Feng Y (2004): Developmentallyprogrammed FMRP expression in oligodendrocytes: a potential role of FMRP in regulating translation in oligodendroglia progenitors. Hum Mol Genet 13: 79-89.
179. Wang XJ (2010): Neurophysiological and computational principles of cortical rhythms in cognition. Physiol Rev 90: 1195-1268.
180. Wilson BM, Cox CL (2007): Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. Proc Natl Acad Sci USA 104: 2454-2459.
181. Wilson RI, Nicoll RA (2002): Endocannabinoid signaling in the brain. Science 296: 678-682.
182. Yamada J, Okabe A, Toyoda H, Kilb W, Luhmann HJ, Fukuda A (2004): Cl - uptake promoting depolarizing GABA actions in immature rat neocortical neurones is mediated by NKCC1. J Physiol (Lond) 557: 829-841.
183. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP (2005): Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49: 1053-1066.
184. Yu W, Jiang M, Miralles CP, Li RW, Chen G, De Blas AL (2007): Gephyrin clustering is required for the stability of GABAergic synapses. Mol Cell Neurosci 36: 484-500.
185. Zhang L, Alger BE (2010): Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci 30: 5724-5729.
186. Zoghbi HY (2003): Postnatal neurodevelopmental disorders: meeting at the synapse? Science 302: 826-830. (Pubitemid 15104762)